Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone SR/Bupropion SR for Major Depression in Overweight or Obese Subjects
NCT00624858Phase 2Completed
- Sponsor
- Orexigen Therapeutics
- Start
- Jan 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naltrexone, bupropion in major depressive disorder (MDD), sponsored by Orexigen Therapeutics. Started Jan 2008; status: completed.
02
Drugs
naltrexonebupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00624858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00624858.